Brokers Set Expectations for JANX FY2026 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Janux Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($4.43) per share for the year. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share.

A number of other brokerages have also recently commented on JANX. Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Wedbush reiterated an "outperform" rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Janux Therapeutics has a consensus rating of "Buy" and a consensus price target of $95.25.

Janux Therapeutics Trading Up 1.2%

JANX traded up $0.30 during trading on Tuesday, hitting $26.24. The company's stock had a trading volume of 601,113 shares, compared to its average volume of 867,976. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -22.43 and a beta of 2.96. The business's fifty day simple moving average is $27.00 and its 200 day simple moving average is $37.52. Janux Therapeutics has a twelve month low of $22.48 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. abrdn plc purchased a new position in Janux Therapeutics in the fourth quarter valued at $3,430,000. Lester Murray Antman dba SimplyRich raised its position in shares of Janux Therapeutics by 205.3% during the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after acquiring an additional 16,351 shares in the last quarter. Legato Capital Management LLC acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth about $347,000. Rhumbline Advisers lifted its stake in Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after purchasing an additional 599 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in Janux Therapeutics by 84.6% in the fourth quarter. New York State Common Retirement Fund now owns 15,964 shares of the company's stock valued at $855,000 after purchasing an additional 7,318 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the business's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 8.10% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.